Jacoby R, Smith AD, Refsum H (2015) Oxford Project to Investigate Memory and Ageing - OPTIMA University of Oxford
Web URL: Further information on OPTIMA and VITACOG is available via the University of Oxford website here
Elevated blood concentrations of total homocysteine and low-normal concentrations of B vitamins (folate, vitamin B12 and vitamin B6) are candidate risk factors for both Alzheimer’s disease and vascular dementia.
Raised plasma total homocysteine is a strong prognostic marker of future cognitive decline.
Low-normal concentrations of the B vitamins, the main determinant of homocysteine concentrations occur in particularly vulnerable sections of the population, such as infants and the elderly.
VITACOG, a two-year randomised, placebo-controlled pilot trial, was developed as part of the Oxford Project to Investigate Memory and Ageing (OPTIMA) in order to determine the effect of treatment (vitamins B6, B12 and folic acid) on the rate of shrinkage of the brain and on memory function in people over 70 years with Mild Cognitive Impairment (MCI).
Additional objectives were to determine
Participants had neuropsychological assessments, MRI brain imaging, blood and urine tests and examination of vital signs (heart rate and blood pressure).
And for some of the key research papers from OPTIMA / VITACOG, see: